Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

In order to evaluate the potential synergistic activity of nivolumab and ipilimumab and also
because there may be differences in biology between tumors which are stable or responding to
therapy and those that are clinically progressing, this study, CA209064, looked at two
sequential combination regimens in which the second agent is administered immediately after a
pre-specified duration of therapy with the first agent and not delayed until the time of
progression after the first agent. This sequential study design looked at pharmacodynamic
changes during treatment with one agent which may predict clinical activity to subsequent
treatment with the alternate agent. This was done because it has not been scientifically
proven whether or not the order in which nivolumab and ipilimumab are given is clinically
important.

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Histologically confirmed unresectable Stage III or IV melanoma

- Treatment-naive or experienced disease recurrence or progression during or after one
prior systemic regimen for advanced disease

- Measurable disease by Computed Tomography/Magnetic resonance imaging (CT/MRI) per
Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

- Known BRAF V600 mutation status or consent to BRAF V600 mutation testing

- Sufficient tumor tissue accessible for baseline and post-treatment biopsies.

Exclusion Criteria:

- Active central nervous system (CNS) metastases

- Carcinomatous meningitis

- Active, known or suspected autoimmune disease

- Condition requiring systemic treatment with either corticosteroids (>10 mg daily
prednisone equivalent) or other immunosuppressive medications within 14 days of
randomization

- Prior therapy with anti-Programmed Death-1 (PD1), anti-Programmed Death-Ligand 1
(PD-L1), anti-PD-L2, anti-CD137, or anti-CTLA-4 (cytotoxic T lymphocyte antigen 4)
antibody

- Prior treatment with other immunotherapies

- Prior therapy with BRAF inhibitor within 6 weeks of enrollment